Dyck

Pages

1980 Vecernje Novosti Rubin Brandy
1980 Vecernje Novosti Rubin Brandy
NA 26. MEDJUNARODNOM SAJMU VINA U LJUBLJANI ,,RUBIN’’ VINJAK SAMPION OPET Prema jednoglasnoj odluci zirija, ovo visoko medjunarodno priznanje za kvalitet ,,Rubinov” vinjak osvojio je u konkurenciji 179 uzoraka iz 19 zemalja (opsirnije na strani 15.), AT THE 26TH INTERNATIONAL WINE FAIR IN LJUBLJANA "RUBIN" BRANDY IS CHAMPION ONCE AGAIN According to the unanimous decision of the jury, this high international recognition for quality that was awarded to "Rubin's" brandy won against a strong competition of 179 samples from 19 countries (more on this topic on page 15)., An advertisement for Rubin’s brandy. This is more-so an announcement for Rubin Brandy winning at the Ljubljana International Wine Fair against a competition of 179 samples from 19 countries. There are no images. There is a large font size for “RUBIN BRANDY IS CHAMPION ONCE AGAIN”, but the rest of the ad has a smaller font size. There is a red border around the ad.
1980 Vecernje Novosti Valjevo Brewery
1980 Vecernje Novosti Valjevo Brewery
6 of these identical ads in Vecernje Novosti 1980., 1860 Valjevska Pivara TRI VISOKA MEDJUNARODNA PRIZNANJA ZA KVALITET, 1860 Valjevo Brewery THREE HIGH INTERNATIONAL AWARDS FOR QUALITY, An advertisement for Valjevo Brewery, based in Valjevo. There is a logo for the brewery on the top of the ad with a letter P and the date 1860. Valjevo Brewery is written in cursive writing. The ad mentions this brewery has won 3 international awards.
1980 Vecernje Novosti White and Red Milion Wine
1980 Vecernje Novosti White and Red Milion Wine
NAVIP ZLATNA MEDALJA ZA KVALITET ZA ,,BELI” I ,,CRVENI” MILION NA SAJMU ,,SKENDERIJA 80” stp. 16 NAVIP, NAVIP GOLD MEDAL FOR THE QUALITY OF THEIR “WHITE” AND “RED” MILION AT THE “SKENDERIJA 80” FAIR stp. 16 NAVIP, An advertisement for the Beli (white) and Crveni (red) Milion wine by Navip. The ad mentions these wines won the gold medal at the Skenderija fair. All letters are the same large font and in black, except for NAVIP written on the left and right side of the ad in red font. There is a red border around the ad. There are no images.
1981 AJP Adapin
1981 AJP Adapin
when depressive symptoms come in a cluster of blues… adapin (doxepin HCl) helps patients see life in all its colours. Improvements noted at one week. Depressed patients often present with fatigue, anorexia, anxiety, mood swings, loss of interest, and most frequently, early awakening and insomnia. In a summation of 9 clinical studies involving 198 patients, significant clinical improvement was noted after the first week of doxepin treatment. However, optimal antidepressant response may not be evident for two to three weeks. Normalized sleep patterns. In a study of clinically depressed patients with symptoms of insomnia, treatment with doxepin significantly reduced difficulty falling asleep, difficulty staying asleep and frequency of early morning awakening. Low potential for cardiotoxicity. The indigence of tachycardia and hypotension, which have been observed during treatment with tricyclic antidepressants, have been reported infrequently with doxepin. In 452 patients given doxepin, the incidence of tachycardia was 2.88%; in 485 patients, the incidence of hypotension was 2.62%. Now available… 75 mg capsules for h.s. dosage. Adapin… effective single-entity drug with antidepressant and antianxiety effects, doxepin HCl, Penwalt, woman in blue blankets and robe, in chair looking depressed, in bed looking like she can't sleep, and larger face looking anxious. Pile of blue clothing. Bar graph showing effectiveness on next page.
1981 AJP Asendin
1981 AJP Asendin
Because every day counts in the relief of depression. New Asendin Amoxapine. ".. A physician cannot judge just which depressive day will be one too many". Now …in depression. Your patients can begin to feel better and function better- not just sleep better- in days not weeks. Rapid antidepressant action that begins sooner than with amitriptyline or imipramine. Rapidly relievs important symptoms of depression, often in the early days of therapy. Onset of action as early as the fourth day was demonstrated in specially-designed studies involving 93 patients. Asendin amoxapine provided greater relief than amitriptyline for key anxiety-depression symptoms on days 4 and 7 of therapy. New Asendin amoxapine, rapidly improves a broad range of depressive symptoms, not just insomnia for earlier remission and return to normal activities. In controlled clinical studies, asendin exerted a more rapid overall positive influence on the depressive state than was achieved with imipramine. Rapidly relieves sleep disturbances in most patients, usually without impairment of daytime alertness… patient gets a restful night's sleep without oversedation. Asendin is similar to amitriptyline in its ability to relieve the insomnia associated with depression. Daytime drowsiness is usually not a problem. However, patients should be advised that if drowsiness is experienced they should avoid driving automobiles or operating heavy machinery. Provide assurance and confidence in antidepressant therapy. No serious cardiotoxicity reported to date with asendin amoxapine. Excellent patient tolerance helps assure a high level of patient comfort and compliance. Low incidence of anticholinergic effects help ensure patient comfort. New asendin amoxapine. Now, for your next depressed patient. Because every day counts in the relief of depression, amoxapine, Lederle laboratories, man encased in plaster cast, in depressed stance on chair. Breaks out of cast and walks free, in business clothing. Leaves pile of plaster behind. seriously plays to physician fear.
1981 AJP Ativan
1981 AJP Ativan
a mixed syndrome. When drug intervention is indicated in patients whose anxiety is accompanied by depressive symptoms, the choice, essentially, is among three basic strategies: 1. an antidepressant. 2. a tranquilizer. 3. a combination of 1 and 2. with respect to strategy 2, you should know that ativan (lorazepan) has been shown to be statistically and clinically significantly effective in alleviating the anxiety component of this mixed syndrome, in common protocol controlled studies of 653 patients (337 on Ativan). Since ativan was also found to be compatible with tricyclics, if you opt for this strategy (3) your patient has the benefit of rapid anxiolytic action, absence of long-acting metabolites, and rapid clearance when you decide to discontinue ativan. All benzodiazepines, however, including ativan produce added CAN depressant effects when administered with alcohol and other CNS depressants. In either case, Ativan offers you the convenience of a b.i.b schedule and a flexibility not possible with any fixed combination, lorazepam, Wyeth Laboratories, artistic image of two faces, attached/ blurring in to one another. One face looks depressed, one looks anxious
1981 AJP Ativan
1981 AJP Ativan
for short-term therapy, a short-acting agent. Short period of accumulation, unlike long-acting benzodiazepines, which accumulate for as long as 20 days before reaching steady state, Ativan accumulates for only 2 to 3 days, thus lessening the likelihood of excessive sedation. Drowsiness that sometimes occurs with the first few doses is usually mild and transistory. Short half-life: the 12-hout half life of ativan is consistent with b.i.d dosage, and drug hangover has not been a problem. Short period of elimination: once you discontinue ativan, it will be out of your patient's system 4 days after the final dose- in contrast to long-acting benzodiazepines, which require up to 2 weeks for elimination. Other advantages: since ativan forms no active metabolites, there is less work for the liver. No significant drug interactions have been reported between ativan and more than 300 drugs taken concurrently. (all benzodiazepines produce CNS depression when taken with alcohol or other depressants.) Ativan for anxiety associated with depressive symptoms, lorazepam, Wyeth Laboratories, image of brain (looks like plasticine), cross section, arrows going in. Cross section of kidney, arrows going out.
1981 AJP Centrax
1981 AJP Centrax
Presence of mind in antianxiety therapy. Centrax (prazepam) offers low potential for sedation. This can be a special attribute in an antianxiety agent. Clouded thinking has no place in the work environment, where psychomotor precision is often important. Moreover, altered mentation may pose additional problems for patients at home or on busy streets, where clearness of mind is just as essential. Noticeable dose-related transient peaks of drug effect are infrequent with centrax, the antianxiety agent that offers these advantages: drowsiness is infrequent (6.8%) at recommended doses. A psychomotor performance study in a normal population showed no statistical significant impairment with prazepam at recommended doses. Changes in mentation are minimized, light headedness is infrequent (6.8%), and signs of altered states of mind are rare., prazepam, parke-davis, hands working on a control board, soldering something on a computer. brain as computer?
1981 AJP Centrax
1981 AJP Centrax
Presence of mind in antianxiety therapy. Centrax (prazepam) low potential for sedation. This is important for patients, since clouded thinking has no place in the work environment or at home. Centrax is the antianxiety agent that offers these advantages: drowsiness is infrequent (6.8%) at recommended doses. A psychomotor performance study in a normal population showed no statistically significant impairment with prazepam at recommended doses. Changes in medication are minimized, light headedness is infrequent (6.8%) and signs of altered states of mind are rare., prazepam, Parke-Davis, woman's hands with pink painted nails at a sewing machine. reduced side effects that impede ability to work.
1981 AJP Eskalith
1981 AJP Eskalith
helps weather the manic storm. Maintenance therapy with eskalith lithium carbonate. In hemic-depressive patients with a history of mania, Eskalith: prevents or diminishes the intensity of future episodes, can increase the intervals between episodes, helps patients function within normal limits, lithium carbonate, SK&F, wavey ocean with jagged rocks sticking out, sun setting. Illustration of pill bottle on opposite page
1981 AJP Haldol
1981 AJP Haldol
Profiles in successful patient management. What do they have in common? One neuroleptic from starting dose through long term maintenance. In the interest of exposing patient to the smallest number of medications, the same neuroleptic often can and should be used from starting dose through all phases of therapy- including long term maintenance. In this connection, haldol haloperidol offers a number of distinct advantages. Widest range of dosage options: Haldol is effective- with a favourable safety profile- at both the low doses used in maintaining many outpatients and at the higher doses sometimes required for psychiatric emergencies or for patients refractory to treatment. Minimal sedative, cardiovascular and anticholinergic effects. Patients taking haldol for either initial therapy of long-term stabilization are unlikely to experience undue sedation, hypotension, blurred vision, dry mouth or constipation. Although extrapyramidal symptoms have been reported frequently, they are readily controled with dosage adjustment of antiparkinson medication. They may also diminish spontaneously with continues use of haldol. Haldol (haloperidol). One neuroleptic from starting dose through long-term maintenance. Effective, with a favourable safety profile, at the very low doses often prescribed for ambulatory psychotics, effective, with a wide safety margin at the higher doses sometimes required to treat acute phases of psychosis, easy switchover from IM to oral forms, tasteless, odorless, colourless concentrate permi.. Dosage adjustments in small increments, haloperidol, McNeil Pharmaceutical, large graph showing: starting dose, upward adjustment, downward adjustment, maintenance therapy. l pictures of four patients with different ages and symptoms, shows their dosages through these four stages with thick coloured lines. Pills and syringe on op. emphasizes need for only this drug, no other treatment necessary.
1981 AJP Librium
1981 AJP Librium
a legacy of evolution. Increasing evidence links anxiety to phylogenetically ancient brain structures. Catecholamine-rich locus coeruleus has been proposed as one of a number of anatomic structures intricately involved in anxiety. Specific brain binding sites for benzodiazepines appear to be evolutionary legacy shared by most vertebrate species studies. A legacy of excellence. Librium. Chorodiazepoxide HCl/ Roche. The origin of the species. Still a leader after 20 years, chlordiazepoxide HCl, Roche, simple illustrations of brain, then cerebellum, then one neuron. Pill on opposite page. evolutionary (universal, biological)

Pages